Article

sharingdash.medianewsgroup.com on 2024-05-10 15:46

Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge

It may be too late for the FDA to change the sotorasib dosage, although in principle it could demand a new regimen before granting final approval, ...

Related news